2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-153277
    Axl/Mer/CSF1R-IN-2 2394874-63-4 98%
    Axl/Mer/CSF1R-IN-2 (Comp 4) is a Axl, Mer and CSF1R inhibitor.
    Axl/Mer/CSF1R-IN-2
  • HY-153279
    5-LOX-IN-3 1875061-47-4 98%
    5-LOX-IN-3 (Compound 14) is a 5-Lipoxygenase inhibitor (IC50: <1 μM). 5-LOX-IN-3 can be used for research of inflammatory diseases, cancer, stroke and Alzheimer's disease.
    5-LOX-IN-3
  • HY-153427
    Tau protein aggregation-IN-1 916179-45-8 98%
    Tau protein aggregation-IN-1 (Compound 0c) is a Tau protein aggregation inhibitor. Tau protein aggregation-IN-1 can be used in the study of protein folding disorders such as Alzheimer's disease, dementia, Parkinson's disease, Huntington's disease and prion-based spongiform encephalopathies.
    Tau protein aggregation-IN-1
  • HY-153430
    Aβ/tau aggregation-IN-3 1210750-32-5 99.70%
    Aβ/tau aggregation-IN-3 is a potent amyloid protein aggregation inhibitor with an IC50 of 0.85 μM by Aβ-Thioflavin T (Aβ-ThT) functional aggregation assay. Aβ/tau aggregation-IN-3 has anti-amyloid activity.
    Aβ/tau aggregation-IN-3
  • HY-153431
    TRV-1387 1569645-63-1 98%
    TRV-1387 is a benzofurazan that inhibits the aggregation of tau and amyloid-β.
    TRV-1387
  • HY-153432
    TRV-7019 2598164-15-7 99.64%
    TRV-7019 is a BBB-penetrable radioligand for brain imaging that target butyrylcholinesterase. TRV-7019 can be used for the diagnosis of an amyloid disease, multiple sclerosis, a brain tumor, or butyrylcholinesterase activity.
    TRV-7019
  • HY-15344A
    (S,S)-Ketone monoester 1251829-99-8 98%
    (S,S)-Ketone monoester is a (S,S)-enantiomer of Ketone monoester (HY-15344). Ketone monoester elevates the AcAc and acetone levels, thereby produces sustained ketosis and significantly delays central nervous system oxygen toxicity (CNS-OT) seizures.
    (S,S)-Ketone monoester
  • HY-153458
    Orexin receptor modulator-1 2125735-57-9 98%
    Orexin receptor modulator-1 is an orexin receptor modulator. Orexin receptor modulator-1 can be used for the research of substance addiction, panic disorder, anxiety, post-traumatic stress disorder, pain, depression, seasonal affective disorder, an eating disorder, or hypertension.
    Orexin receptor modulator-1
  • HY-153463
    Diosuxentan 2305865-93-2 98%
    Diosuxentan is an inhibitor of ETA. Diosuxentan can be used in research for cardiovascular, renal and neuronal inflammation diseases.
    Diosuxentan
  • HY-153472
    VMAT2-IN-2 tosylate 2608770-12-1 98%
    VMAT2-IN-2 tosylate is a potent VMAT2 inhibitor. VMAT2-IN-2 tosylate can be used in research of tardive dyskinesia.
    VMAT2-IN-2 tosylate
  • HY-153528
    DMAA 73671-86-0 98%
    DMAA is an indirect sympathomimetic amine. DMAA constricts blood vessels and raises blood pressure. DMAA can be used for neurological and cardiovascular disease research.
    DMAA
  • HY-153548
    P2X2/3 modulator-1 1217483-98-1 98%
    P2X2/3 modulator-1 (Compound 46) is a P2X2/3 modulator. P2X2/3 modulator-1 can be used in the study of pain, central nervous system disorders and inflammation.
    P2X2/3 modulator-1
  • HY-153560
    Lp-PLA2-IN-14 2756855-66-8 98%
    Lp-PLA2-IN-14 (Compound 19) is an Lp-PLA2 inhibitor with a pIC50 of 8.4 against rhLp-PLA2. Lp-PLA2-IN-14 can be used for the research of neurodegenerative related diseases, such as Alzheimer Disease (AD), glaucoma, age-related macular degeneration (AMD) or cardiovascular diseases including atherosclerosis and the like.
    Lp-PLA2-IN-14
  • HY-153561
    Lp-PLA2-IN-15 1865796-11-7 98%
    Lp-PLA2-IN-15 (example 2) is a lipoprotein-associated phospholipase A2 (Lp-PLA 2) inhibitor, which can be used in the research of Alzheimer's disease, etc.
    Lp-PLA2-IN-15
  • HY-153687
    SORT-PGRN interaction inhibitor 2 1008233-79-1 98%
    SORT-PGRN interaction inhibitor 2 is a SORT-PGRN inhibitor that can decreases SORT1 protein expression and increases extracellular PGRN secretion in mammalian cell lines. SORT-PGRN interaction inhibitor 2 can be used for neurological disease research.
    SORT-PGRN interaction inhibitor 2
  • HY-153688
    SORT-PGRN interaction inhibitor 3 2691846-87-2 98%
    SORT-PGRN interaction inhibitor 3 (Compound 13) is a SORT-PGRN interaction inhibitor (IC50: 0.17 μM). SORT-PGRN interaction inhibitor 3 can be used for research of neurodegenerative diseases.
    SORT-PGRN interaction inhibitor 3
  • HY-153717
    LAU-0901 727358-25-0 98%
    LAU-0901, a PAF receptor antagonist, possesses highly neuroprotective activity. LAU-0901 inhibits apoptosis.
    LAU-0901
  • HY-153746
    Kv3 modulator 5 1380696-68-3 98%
    Kv3 modulator 5 (Example 5) is a Kv3 channel modulator. Kv3 modulator 5 increases the Kv3.2 current. Kv3 modulator 5 can be used for research of hearing disorders.
    Kv3 modulator 5
  • HY-153747
    Casein kinase 1δ-IN-4 851168-98-4 ≥98.0%
    Casein kinase 1δ-IN-4 (compound 567) is a potent casein kinase 1δ inhibitor. Casein kinase 1δ-IN-4 has the potential for the research of Alzheimer's disease.
    Casein kinase 1δ-IN-4
  • HY-153760
    GSK-3β inhibitor 14 863004-48-2 99.92%
    GSK-3β inhibitor 14 (Compound 6i), benzothiazepinone derivative, is a weak GSK-3β inhibitor (IC50 >100 μM).
    GSK-3β inhibitor 14
Cat. No. Product Name / Synonyms Application Reactivity